Mod­er­na seeks to dis­miss Al­ny­lam suit over Covid-19 vac­cine com­po­nent, claim­ing wrong venue

RNAi ther­a­peu­tics jug­ger­naut Al­ny­lam Phar­ma­ceu­ti­cals made a splash in March when it sued and sought mon­ey from both Pfiz­er and Mod­er­na re­gard­ing their use of Al­ny­lam’s biodegrad­able lipids, which Al­ny­lam claims have been in­te­gral to the way both com­pa­nies’ mR­NA-based Covid-19 vac­cines work.

But now, Mod­er­na lawyers are fir­ing back, telling the same Delaware dis­trict court that Al­ny­lam’s claims can on­ly pro­ceed against the US gov­ern­ment in the Court of Fed­er­al Claims be­cause of the way the com­pa­ny’s con­tract is set up with the US gov­ern­ment. The US has spent al­most $10 bil­lion on Mod­er­na’s Covid-19 vac­cine so far.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER